AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$NTRA

Moshkevich Solomon sold $906K of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,410 shares of Natera, Inc. (NTRA) at an average of $265.58 ($259.98–$268.70, $0.91M total) across 7 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Aug 6, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, share count, and the fact it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh insider-selling datapoint, but it is not tied to earnings, guidance, or regulatory/product events in the text.

03

What to watch

Traders may focus on whether multiple insiders are selling concurrently or whether the sale coincides with other company-specific catalysts, which are not present in this text.

Relevance 4/10Novelty 5/10Timing: filed Aug 5, transaction dated Aug 3

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows President, Clinical Diagnostics Moshkevich Solomon sold $905,626 of NTRA shares via a 10b5-1 plan on Aug 3.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary-source Form 4 and the transaction size is moderate, but the presence of a pre-arranged 10b5-1 plan reduces interpretive signal.

Market effects

Sector

Minimal; insider sales under 10b5-1 typically do not reset sector expectations for diagnostics/biotech.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price impact could be negligible.

Key entities

  • issuer
    Natera, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Moshkevich Solomon

    President, Clinical Diagnostics; sold 3,410 shares of NTRA on Aug 3 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min